CRCM  Vol.2 No.1 , March 2013
Sustained long-term clinical and radiological response with sunitinib for metastatic renal-cell carcinoma (RCC)
ABSTRACT

The authors herein report the case of a 67-year-old woman with metastatic renal-cell carcinoma (RCC), who has had a sustained clinical and stable radiological response to long-term therapy with an oral multi-targeted tyrosine kinase inhibitor (TKI), sunitinib with minimal lasting toxicity.


Cite this paper
Quintyne, K. , Neenan, T. , Wallis, F. and Gupta, R. (2013) Sustained long-term clinical and radiological response with sunitinib for metastatic renal-cell carcinoma (RCC). Case Reports in Clinical Medicine, 2, 29-31. doi: 10.4236/crcm.2013.21008.
References
[1]   Escudier, B., Eisen, T., Porta, C., et al. (2012) Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 23, vii65-vii71. doi:10.1093/annonc/mds227

[2]   Motzer, R.J., Hutson, T.E., Tomczak, P., et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine, 356, 115-124. doi:10.1056/NEJMoa065044

[3]   Motzer, R.J., Hutson, T.E., Tomczak, P., et al. (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 27, 3584-3590. doi:10.1200/JCO.2008.20.1293

[4]   Heng, D.X., Xie, W., Regan, M.M., et al. (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. Journal of Clinical Oncology, 27, 5794-5799. doi:10.1200/JCO.2008.21.4809

[5]   Molina, A.M., Ginsberg, M.S. and Motzer, R.J. (2011) Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib. Medical Oncology, 28, 1527-1529. doi:10.1007/s12032-010-9640-y

[6]   Cohen, H.T. and McGovern, F.J. (2005) Renal-cell carcinoma. New England Journal of Medicine, 353, 2477-2490. doi:10.1056/NEJMra043172

[7]   Motzer, R.J. (2003) Renal cell carcinoma: A priority malignancy for development and study of novel therapies. Journal of Clinical Oncology, 21, 1193-1194. doi:10.1200/JCO.2003.12.072

[8]   Yagoda, A., Abi-Rached, B. and Petrylak, D. (1995) Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Seminars in Oncology, 22, 42-60.

[9]   Schoffski, P., Bukowski, R., Flodgren, P., et al. (2009) Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: Case reports. Annals of Oncology, 20, i25-i30. doi:10.1093/annonc/mdp076

[10]   http://www.bccancer.bc.ca/NR/rdonlyres/EE7AE153-718A-4AB3-A01F-66D6E49A8DC1/53411/sunitinibmonograph_1October2011.pdf (Accessed 12 November 2012)

 
 
Top